Trazodone for SSRI-sexual Dsyfunction
- Registration Number
- NCT01097980
- Lead Sponsor
- Beitou Armed Forces Hospital, Taipei, Taiwan
- Brief Summary
The aim of this study is to investigate the efficacy of trazodone in the treatment of selective serotonin reuptake inhibitor(s) associated sexual dysfunction. The secondary domains assessed were the relationship between 5-HT2A polymorphism and treatment efficacy.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 56
Not provided
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description Placebo Placebo Patients received placebo Trazodone Trazodone Trazodone versus placebo in a randomized, double-blind manner
- Primary Outcome Measures
Name Time Method The differences between trazodone and placebo in the Arizona Sexual Experiences Scale-Chinese Version scale at the end of week 6 were used as the primary study outcomes. week 0 and week 6
- Secondary Outcome Measures
Name Time Method The association between 5-HT2A polymorphism and the changes in Arizona Sexual Experiences Scale-Chinese Version scale were evaluated. week 6 The secondary domains assessed were the difference between trazodone and placebo in the Clinical Global Impression scale, 10-point Visual Analogue Scale, Hamilton Depression Rating Scale, and Hamilton Anxiety Rating Scale at the end of week 6. Besides, relationships between 5-HT2A polymorphism and the changes in Arizona Sexual Experiences Scale-Chinese Version scale were also evaluated.
Trial Locations
- Locations (1)
Department of Psychiatry, Beitou Armed Forces Hospital
🇨🇳Taipei, Taiwan